文献速递药物不良反应与药物警戒

瑞波西利上市后安全性:FAERS数据库真实世界分析

Comprehensive safety assessment of ribociclib: A real-world analysis using the FDA Adverse Event Reporting System (FAERS) database.
PubMed 文献 · Br J Clin Pharmacol · 2025-09-01

本研究基于FAERS数据库2017年第一季度至2023年第一季度的数据,采用比例失衡分析(ROR、PRR、BCPNN、EBGM)挖掘瑞波西利相关不良事件信号。共获得9533份瑞波西利不良事件报告,信号涉及23个系统器官分类,常见于肿瘤和血液毒性,并发现左心房扩大、丹毒、多神经病、肾小球滤过率下降、味觉丧失等非预期信号。

要点

  • 瑞波西利相关不良事件信号涉及23个系统器官分类。
  • 常见信号包括肿瘤相关事件和血液学毒性。
  • 发现左心房扩大、肾小球滤过率下降等非预期信号。

核心结论

  • 瑞波西利治疗期间存在潜在的新发和非预期不良事件信号,需加强上市后监测。

研究设计与样本

  • 基于FAERS数据库2017年第一季度至2023年第一季度数据的回顾性比例失衡分析,共纳入9533份瑞波西利不良事件报告。

主要发现

  • 经四种算法同时符合的信号涉及23个系统器官分类。
  • 常见显著系统器官分类包括良性、恶性及未特指肿瘤和免疫系统疾病等。
  • 显著信号映射至首选术语后涉及肿瘤发生和血液学毒性。
  • 非预期显著不良事件包括左心房扩大、丹毒、多神经病、肾小球滤过率下降和味觉丧失等。

临床怎么用

  • 临床使用瑞波西利时应关注血液学毒性及肿瘤相关事件。
  • 对左心房扩大、肾小球滤过率下降等非预期信号保持警惕。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Ribociclib is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor that was approved by the US Food and Drug Administration (FDA) in 2017 for the treatment of advanced hormone receptor-positive (HR+) breast cancer. The presented study aimed to evaluate the ribociclib-associated adverse events (AEs) through data mining of the US Food and Drug Administration Adverse Event Reporting System (FAERS). METHODS: Data were collected from the FAERS database covering the period from the first quarter of 2017 to the first quarter of 2023. Disproportionality analyses were employed to quantify the associated AE signals of ribociclib and detect the risk signals using reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the empirical Bayes geometric mean (EBGM), and MedDRA was used to systematically classify the results. RESULTS: A total of 9533 AE reports of ribociclib were obtained using data from the FAERS database, and ribociclib-associated AEs targeted 23 system organ classes (SOCs) after conforming to the four algorithms simultaneously. The common significant SOCs were identified, including benign, malignant and unspecified neoplasms, immune system disorders, etc. The significant AE signals were then mapped to preferred terms (PTs), associated with tumorigenesis and haematologic toxicity, which have emerged in the study, usually reported in patients with ribociclib. Of note, unexpected significant AEs, including "left atrial enlargement", "erysipelas", "polyneuropathy", "glomerular filtration rate decreased", "ageusia", and so on, were uncovered in the label. CONCLUSIONS: Our study provides real-world safety data on post-marketing surveillance and highlights potential new and unexpected AE signals during ribociclib treatment.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Luo L, Wang Y, Fu Y, et al. Comprehensive safety assessment of ribociclib: A real-world analysis using the FDA Adverse Event Reporting System (FAERS) database. Br J Clin Pharmacol. 2025. PMID: 40891100. doi:10.1002/bcp.70265

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。